Compare Invesco Ltd. (IVZ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs BIO-TECHNE Corp — how do they compare? Invesco Ltd. trades at $31.16 (market cap $14.01B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays the higher dividend (2.71%). Which is the better fit depends on your goals.
| IVZ | TECH | |
|---|---|---|
Market Cap | $14.01B | $11.24B |
Sector | Financials | Health |
52-Week High | $32.01 | $72.29 |
52-Week Low | $20.45 | $43.31 |
Enterprise Value | $24.18B | $11.32B |
Dividend Yield | 2.71% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $31.58, near its 52-week high, with a bullish technical signal from moving averages and recent record inflows driving AUM growth. The company reported mixed quarterly EPS results but shows improving cash flow trends, with 2025 operating cash flow at $1.53 billion. Analyst consensus is divided, with 42.9% buy ratings and a $32.50 price target, while negative net income margins and ROE highlight profitability challenges.
The outlook is cautiously optimistic due to strong institutional interest and dividend consistency, but risks include expense pressures and volatile earnings. Investors should weigh the bullish technicals and asset growth against fundamental weaknesses in profitability and margin compression.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
